Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Anastrozole | hCG (Human Chorionic Gonadotropin) | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly. | Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance. |
| Timing | Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control. | Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days. |
| Cycle Duration | Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose. | Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery. |
| Evidence Level | strong_human | strong_human |
Anastrozole is a potent, selective, non-steroidal third-generation aromatase inhibitor that competitively binds the heme group of cytochrome P450 aromatase (CYP19A1), blocking the conversion of testosterone to estradiol and androstenedione to estrone. In men on TRT, this reduces circulating estradiol by 50-80%, shifting the testosterone-to-estradiol ratio favorably. Estrogen suppression releases hypothalamic negative feedback, increasing GnRH, LH, and FSH secretion in non-TRT contexts. Complete estrogen ablation is detrimental to bone density, lipid metabolism, and cognitive function.
Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly.
Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control.
Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose.
hCG mimics luteinizing hormone (LH) by binding the LH/CG receptor on testicular Leydig cells, activating the cAMP-PKA signaling cascade that upregulates steroidogenic acute regulatory protein (StAR) and CYP11A1, driving cholesterol conversion to pregnenolone and downstream testosterone synthesis. By maintaining intratesticular testosterone (ITT) levels during exogenous testosterone administration, hCG preserves Leydig cell function, spermatogenesis, testicular volume, and the production of neurosteroids (pregnenolone, DHEA) and estradiol within the testes.
Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance.
Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days.
Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →